Halopid5 mg/ml

Halopid 5 mg/ml is a first-generation (typical) antipsychotic used for:

• Treatment of schizophrenia
• Control of tics and vocal utterances of Tourette's disorder, in adults and children
• Management of severe behavioural problems in children (short-term, when other treatments have failed), per some regulatory approvals

Important limitation of use: Halopid 5 mg/ml is not approved for the treatment of dementia-related psychosis; elderly patients with dementia-related psychosis treated with antipsychotic drugs, including Halopid 5 mg/ml, are at increased risk of death.

Contains Halopid 5 mg/ml as the active ingredient, available as oral tablets (commonly 0.5 mg, 1.5 mg, 5 mg, and 10 mg), oral solution, and as Halopid 5 mg/ml lactate injection (for IM or, off-label, IV use) and Halopid 5 mg/ml decanoate injection (a long-acting depot form for IM use only, never IV).

Halopid 5 mg/ml is a potent, first-generation antipsychotic medicine that has been used for decades to treat schizophrenia and, in a different context, to control the tics and vocal outbursts of Tourette's disorder. It works by blocking dopamine receptors in the brain, which reduces hallucinations, delusions, and disorganized thinking. Halopid 5 mg/ml carries a boxed warning: it is not approved for dementia-related psychosis, and elderly patients with dementia treated with antipsychotic drugs, including Halopid 5 mg/ml, face an increased risk of death, mostly from cardiovascular or infection-related causes. It also carries important risks of QT interval prolongation and Torsades de pointes (a dangerous heart rhythm disturbance), particularly with higher doses or IV administration, and, like other antipsychotics, a significant risk of movement disorders including potentially irreversible tardive dyskinesia with longer-term use.

Therapeutic Class: Antipsychotic (First-Generation/Typical)

Halopid 5 mg/ml is primarily metabolized by the liver, and blood levels may increase in patients with hepatic impairment given reduced metabolism and protein binding. It is an inhibitor of the CYP2D6 enzyme, which can raise blood levels of other drugs metabolized through this pathway (such as certain tricyclic antidepressants) when co-administered. Higher-than-recommended doses of any Halopid 5 mg/ml formulation, and IV administration in particular, are associated with an increased risk of QT prolongation and Torsades de pointes.

• Oral tablets or solution can be taken with or without food, at consistent timing as directed
• Injectable forms are administered only by a healthcare professional
• Halopid 5 mg/ml decanoate must never be given intravenously - it is for intramuscular use only
• If Halopid 5 mg/ml lactate is used IV (off-label), continuous ECG monitoring is recommended given increased QT prolongation risk with this route
• Rise slowly from sitting or lying positions, given the risk of dizziness from blood pressure changes

The following interactions require careful assessment:

• Other QT-prolonging medicines (certain antiarrhythmics, some antibiotics, some antidepressants): combining with Halopid 5 mg/ml increases the risk of dangerous heart rhythm disturbances; avoid combinations where possible and monitor ECG if necessary.
• CYP2D6 substrate medicines (such as certain tricyclic antidepressants): Halopid 5 mg/ml inhibits this enzyme and can raise their blood levels; dose adjustment of the other medicine may be needed.
• CYP3A4 or CYP2D6 inhibitors (such as ketoconazole or paroxetine): can increase Halopid 5 mg/ml blood levels and associated QT prolongation risk; dose reduction of Halopid 5 mg/ml may be necessary if combined.
• Other CNS depressants, including alcohol: additive sedative effects.
• Antihypertensive medicines: Halopid 5 mg/ml can cause low blood pressure, particularly orthostatic hypotension; monitor blood pressure if combined.
• Levodopa and dopamine agonists: Halopid 5 mg/ml's dopamine-blocking action may reduce their effectiveness for Parkinson's disease.

Common side effects

• Sedation
• Dizziness
• Extrapyramidal symptoms: muscle stiffness, tremor, restlessness (akathisia)
• Dry mouth
• Weight changes

Serious side effects (boxed warning and other important effects - require prompt medical attention)

• Increased mortality in elderly patients with dementia-related psychosis: Halopid 5 mg/ml is not approved for this use, and elderly dementia patients treated with antipsychotics face an increased risk of death, mostly from cardiovascular causes (such as heart failure or sudden death) or infection (such as pneumonia).
• QT prolongation and Torsades de pointes: sudden death, irregular heartbeat, or fainting have been reported, particularly with higher doses or IV use; ECG and electrolyte monitoring are recommended, especially in at-risk patients.
• Neuroleptic malignant syndrome (NMS): a rare but life-threatening reaction with high fever, severe muscle rigidity, altered consciousness, and unstable blood pressure - requires immediate discontinuation and emergency treatment.
• Tardive dyskinesia: involuntary, repetitive movements (often of the face, tongue, or limbs) that can be permanent, even after stopping the medicine; risk increases with dose and duration of treatment, and is highest in elderly patients, particularly women. Report any new involuntary movements promptly.
• Adverse cerebrovascular events (stroke, transient ischaemic attack), including fatalities, reported in geriatric dementia patients treated with antipsychotics.
• Neurological adverse reactions, including worsening of symptoms, in patients with Parkinson's disease or dementia with Lewy bodies, which is why Halopid 5 mg/ml is contraindicated in these conditions.

Pregnancy

Antipsychotic medicines, including Halopid 5 mg/ml, used during the third trimester of pregnancy carry a risk of extrapyramidal and/or withdrawal symptoms in the newborn following delivery; use during pregnancy should be discussed with the treating physician, weighing the risks of untreated psychiatric illness against potential medicine-related risks.

Breastfeeding

Halopid 5 mg/ml passes into breast milk; use during breastfeeding should be discussed with a healthcare professional, with the nursing infant monitored for sedation or feeding difficulties.

• Not for dementia-related psychosis: Halopid 5 mg/ml is not approved for this use, given increased mortality risk in this population; use with caution in geriatric patients with risk factors for cerebrovascular events.
• QT prolongation: use with particular caution in patients with electrolyte imbalance (especially low potassium or magnesium), underlying cardiac abnormalities, hypothyroidism, or family history of long QT syndrome, and in those on other QT-prolonging medicines. Assess QTc via ECG at baseline and during treatment as clinically indicated, and correct electrolyte abnormalities.
• Tardive dyskinesia: counsel patients and caregivers on signs and symptoms; consider drug discontinuation if this develops, since some patients may need continued treatment despite the presence of tardive dyskinesia, per specialist assessment.
• Neuroleptic malignant syndrome: monitor for early signs (fever, rigidity, altered mental status) and discontinue immediately if suspected.
• Higher-than-recommended doses of any Halopid 5 mg/ml formulation, and IV administration specifically, carry a higher risk of QT prolongation and Torsades de pointes.

Overdose of Halopid 5 mg/ml may cause severe extrapyramidal reactions, sedation, hypotension, and dangerous cardiac rhythm disturbances (QT prolongation, Torsades de pointes), which can be fatal. Suspected significant overdose is a medical emergency requiring immediate treatment; management is generally supportive, provided in a medical facility, with continuous cardiac monitoring, airway support, and treatment of any arrhythmia or severe extrapyramidal reaction as clinically indicated.

Store oral tablets and solution at room temperature, protected from light. Store injectable formulations as directed on the product label. Keep out of reach of children.

• Elderly: More susceptible to tardive dyskinesia, orthostatic hypotension, and increased mortality risk if used for dementia-related psychosis (an unapproved use); lower starting doses and slower titration are used.
• Hepatic impairment: Halopid 5 mg/ml blood levels may increase, given reduced hepatic metabolism; use with caution and consider dose reduction.
• Parkinson's disease or dementia with Lewy bodies: Contraindicated, given the risk of significant neurological worsening in these conditions.
• Children: Used for Tourette's disorder and, in some regulatory approvals, severe behavioural problems, with dosing individualized by the treating specialist and close monitoring for movement-related side effects.

Duration depends on the condition being treated - schizophrenia typically requires long-term, ongoing therapy with periodic reassessment of dose and side effects (particularly movement disorders), while Tourette's disorder treatment is individualized based on symptom severity and response, as determined by the treating physician.

Drug Class: Butyrophenone-derivative typical antipsychotic, dopamine D2 receptor antagonist

Halopid 5 mg/ml works primarily by blocking dopamine D2 receptors in the brain, which reduces excessive dopamine signalling believed to underlie the hallucinations, delusions, and disorganized thinking of schizophrenia, and the tic and vocal symptoms of Tourette's disorder. This same dopamine-blocking action in other brain pathways (outside the areas targeted for antipsychotic benefit) is responsible for Halopid 5 mg/ml's characteristic movement-related side effects, including acute extrapyramidal symptoms and, with longer-term use, tardive dyskinesia.

Halopid 5 mg/ml is used in children for control of the tics and vocal utterances of Tourette's disorder, and, in some regulatory approvals, for short-term management of severe behavioural problems when other treatments have failed, with dosing individualized by the treating specialist based on age, weight, and clinical response, and close monitoring for movement-related and other side effects.